특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes

작성자
관리자
작성일
2024-02-01 21:34
조회
64

Choi SW*, Shin JS*, Park SJ*, Jung EH, Park YG, Lee JH, Kim SJ, Park HJ, Lee JH,Park SM, Moon SH*, Ban KW*, Go YY*. Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Research. 2020 Dec;184:104955.


Abstract


Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is considered as the most significant global public health crisis of the century. Several drug candidates have been suggested as potential therapeutic options for COVID-19, including remdesivir, currently the only authorized drug for use under an Emergency Use Authorization. However, there is only limited information regarding the safety profiles of the proposed drugs, in particular drug-induced cardiotoxicity. Here, we evaluated the antiviral activity and cardiotoxicity of remdesivir using cardiomyocytes-derived from human pluripotent stem cells (hPSC-CMs) as an alternative source of human primary cardiomyocytes (CMs). In this study, remdesivir exhibited up to 60-fold higher antiviral activity in hPSC-CMs compared to Vero E6 cells; however, it also induced moderate cardiotoxicity in these cells. To gain further insight into the drug-induced arrhythmogenic risk, we assessed QT interval prolongation and automaticity of remdesivir-treated hPSC-CMs using a multielectrode array (MEA). As a result, the data indicated a potential risk of QT prolongation when remdesivir is used at concentrations higher than the estimated peak plasma concentration. Therefore, we conclude that close monitoring of the electrocardiographic/QT interval should be advised in SARS-CoV-2-infected patients under remdesivir medication, in particular individuals with pre-existing heart conditions.



Keywords

#COVID-19 #SARS-CoV-2  #Human cardiomyocytes #Pluripotent stem cells #Remdesivir

논문확인(클릭시 이동)
전체 52
번호 제목 작성자 작성일 추천 조회
52
[특허] 콘케이브와 진탕배양 기법으로 형성된 전분화능 줄기세포 유래 신경세포 제조방법 및 이에 의해 제조된 3D 신경 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 40
관리자 2024.02.22 0 40
51
[특허] 중간엽줄기세포 패치 공배양 기법을 이용한 투명 배상체 유래 간세포 제조방법 및 이에 의해 제조된 3D 간 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 39
관리자 2024.02.22 0 39
50
[특허] 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
관리자 | 2024.02.22 | 추천 0 | 조회 37
관리자 2024.02.22 0 37
49
[특허] 인공 신경망을 이용한 심장 부정맥 유발약물의 스크리닝 방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
48
[특허] 3 차원 세포 배양용 미세유체칩 및 이를 이용한 3 차원 세포 배양방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
47
Translation reinitiating in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant neg
관리자 | 2024.02.02 | 추천 0 | 조회 49
관리자 2024.02.02 0 49
46
Extracellular matrix cues regulate the differentiation of pluripotent stem cell-derived endothelial cells.
관리자 | 2024.02.02 | 추천 0 | 조회 52
관리자 2024.02.02 0 52
45
Ultraefficient extracellular vesicle–guided direct reprogramming of fibroblasts into functional cardiomyocytes.
관리자 | 2024.02.02 | 추천 0 | 조회 52
관리자 2024.02.02 0 52
44
In vitro maturation of human pluripotent stem cell-derived cardiomyocyte: A promising approach for cell therapy.
관리자 | 2024.02.02 | 추천 0 | 조회 62
관리자 2024.02.02 0 62
43
Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach.
관리자 | 2024.02.02 | 추천 0 | 조회 58
관리자 2024.02.02 0 58